Laboratory Corporation of America® Holdings Announces 2013 Third Quarter Results

Revenue of $1.46 billion , up 3.0% Volume growth of 5.1% Diluted EPS of $1.63 Non-GAAP Adjusted EPS Excluding Amortization of $1.80 Repurchased $288 million of stock, representing 2.9 million shares 2013 Guidance updated for revenue growth of approximately 3% and Adjusted EPS Excluding Amortization

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 1, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 12, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of September 12, 2013 to March 11, 2014 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 3, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York, NY .

LabCorp Applauds National Kidney Foundation’s Guidance about Testing for Chronic Kidney Disease; LabCorp’s CKD Program Provides Clinically Significant Data to Assist Diagnosis and Treatment

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 14, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) applauds the recent recommendation of the National Kidney Foundation (NKF) that all persons age 60 or older receive urine screening for chronic kidney disease (CKD), defined as

Laboratory Corporation of America® Holdings Announces 2013 Second Quarter Results

Revenue of $1.47 billion , up 3.1% Organic volume growth of 1.4% Diluted EPS of $1.62 Non-GAAP Adjusted EPS Excluding Amortization of $1.80 Repurchased $362 million of stock, representing 3.7 million shares 2013 Guidance updated for revenue growth of 2% - 3% and Adjusted EPS Excluding Amortization

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 1, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Announces Availability of Newly Approved Viral Load Assay for Hepatitis C Virus

LabCorp becomes the First Major Clinical Reference Laboratory to Offer the Roche COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 17, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that it is offering the COBAS

LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--May. 8, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas, NV.

LabCorp to Webcast Its Annual Meeting of Stockholders

BURLINGTON, N.C. --(BUSINESS WIRE)--May. 2, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that its Annual Meeting of Stockholders will be webcast live beginning May 8, 2013 at 9:00 a.m. Eastern Daylight Time via the Company Web site at www.labcorp.com .